Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Net (gains)/losses recognized during the period on equity securities

^[1],[2]

$ 67

$ (1,008)

$ (1,590)

Less: Net (gains)/losses recognized during the period on equity securities sold during the period

(1,122)

(1,754)

Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date

$ 32

$ 114

$ 165

[1]

(b)2024 net gains primarily included, among other things, an unrealized gain of $1.0 billion related to our previous investment in Haleon, which was carried at fair value at December 31, 2024 (see Note 2C). 2023 net gains primarily included, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc. and unrealized gains of $297 million related to our investment in Cerevel Therapeutics Holdings, Inc., partially offset by unrealized losses of $292 million related to our investment in BioNTech.

[2]

Reported in Other (income)/deductions––net. See Note 4.